These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 27323074

  • 1. ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer.
    Xu ZC, Cai HZ, Li X, Xu WZ, Xu T, Yu B, Zou Q, Xu L.
    Genet Mol Res; 2016 May 23; 15(2):. PubMed ID: 27323074
    [Abstract] [Full Text] [Related]

  • 2. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL, Li Y, Wang N, Zhou RM, Hu P, Kang S.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov 23; 48(11):847-52. PubMed ID: 24444563
    [Abstract] [Full Text] [Related]

  • 3. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
    Cheng J, Ha M, Wang Y, Sun J, Chen J, Wang Y, Tong C.
    J Cancer Res Clin Oncol; 2012 Feb 23; 138(2):231-8. PubMed ID: 22102173
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
    Ozcan MF, Dizdar O, Dincer N, Balcı S, Guler G, Gok B, Pektas G, Seker MM, Aksoy S, Arslan C, Yalcin S, Balbay MD.
    Urol Oncol; 2013 Nov 23; 31(8):1709-15. PubMed ID: 22863869
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T, Kometani T, Shoji F, Yoshino I, Maehara Y.
    Lung Cancer; 2010 Jan 23; 67(1):101-7. PubMed ID: 19361884
    [Abstract] [Full Text] [Related]

  • 12. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ, Cui S, Yang YZ, Han JQ, Cai BJ, Sheng CF, Ma Y, Wuren T, Ge RL.
    J Cancer Res Ther; 2013 Jan 23; 9(3):410-5. PubMed ID: 24125975
    [Abstract] [Full Text] [Related]

  • 13. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 14. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
    Qian YY, Liu XY, Wu Q, Song X, Chen XF, Liu YQ, Pei D, Shen LZ, Shu YQ.
    Asian Pac J Cancer Prev; 2014 Aug 01; 15(19):8383-90. PubMed ID: 25339033
    [Abstract] [Full Text] [Related]

  • 15. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.
    J Clin Oncol; 2007 Nov 20; 25(33):5172-9. PubMed ID: 18024864
    [Abstract] [Full Text] [Related]

  • 16. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
    Li S, Wu J, Chen Y, Tang W, Peng Q, Deng Y, Xie L, Wang J, Huang S, Li R, Qin X, Zhao J.
    Anticancer Drugs; 2014 Jan 20; 25(1):106-14. PubMed ID: 24025563
    [Abstract] [Full Text] [Related]

  • 17. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.
    Hwang IG, Jang JS, Do JH, Kang JH, Lee GW, Oh SY, Kwon HC, Jun HJ, Lim HY, Lee S, Chi KC, Lee SJ.
    Cancer Chemother Pharmacol; 2011 Oct 20; 68(4):935-44. PubMed ID: 21298384
    [Abstract] [Full Text] [Related]

  • 18. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ.
    Clin Adv Hematol Oncol; 2003 Mar 20; 1(3):162-6. PubMed ID: 16224397
    [Abstract] [Full Text] [Related]

  • 19. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
    Kim KH, Do IG, Kim HS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim DH, Ji SH, Park MJ, Lee J, Park SH, Kwon GY, Lim HY.
    APMIS; 2010 Dec 20; 118(12):941-8. PubMed ID: 21091775
    [Abstract] [Full Text] [Related]

  • 20. Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.
    Nikitas N, Karadimou A, Tsitoura E, Soupos N, Tsiatas M, Karavasilis V, Pectasides D, Pavlidis N, Chrisofos M, Adamakis I, Murray S, Fountzilas G, Dimopoulos MA, Bamias A.
    Pharmacogenomics; 2012 Nov 20; 13(14):1595-607. PubMed ID: 23148636
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.